Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.38 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.36 |
| ▸ | CEPT1 | Q9Y6K0 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29878469 | 0.84 | NPC1 (0.42) | ELANEALDH1A1KDM4E | |
| SCHEMBL19895802 | 0.79 | PSMD14 (0.42) | — | |
| SCHEMBL5537231 | 0.79 | ELANE (0.61) | ELANEFBP1F2RL3AGPAT2ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL28600968 | 0.78 | ELANE (0.59) | ELANEFBP1F2RL3AGPAT2ALDH1A1 | |
| SCHEMBL5537227 | 0.76 | ELANE (0.41) | ELANEFBP1F2RL3AGPAT2P2RY6 | |
| SCHEMBL288843 | 0.76 | ALDH1A1 (0.43) | ELANEFBP1F2RL3AGPAT2P2RY6 | |
| SCHEMBL1821481 | 0.76 | FBP1 (0.45) | ELANEFBP1F2RL3AGPAT2P2RY6 | |
| SCHEMBL9390262 | 0.76 | ELANE (0.39) | ELANEF2RL3ALDH1A1KDM4E | |
| SCHEMBL5485869 | 0.76 | PSMB8 (0.35) | ALDH1A1KDM4E | |
| SCHEMBL9147142 | 0.76 | KDM4E (0.35) | ELANEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025071094-A1 | USES OF MERCAPTO FUNCTIONAL COMPOUND HAVING TYROSINASE INHIBITORY ACTIVITY | 부산대학교 산학협력단 | 2025-04-03 | — | — | WO | claimed |
| WO-2025071094-A1 | USES OF MERCAPTO FUNCTIONAL COMPOUND HAVING TYROSINASE INHIBITORY ACTIVITY | 부산대학교 산학협력단 | 2025-04-03 | — | — | WO | disclosed |
| CN-115124485-B | Sulfoxide-containing benzoxazole derivative, and preparation method and application thereof | 中国医学科学院药物研究所 | 2023-12-15 | — | — | CN | disclosed |
| US-20230312878-A1 | RUBBER COMPOSITION AND CROSSLINKED RUBBER MOLDED PRODUCT | SUMITOMO RUBBER INDUSTRIES, LTD. (JP) | 2023-10-05 | — | — | US | disclosed |
| US-20230312878-A1 | RUBBER COMPOSITION AND CROSSLINKED RUBBER MOLDED PRODUCT | SUMITOMO RUBBER INDUSTRIES, LTD. (JP) | 2023-10-05 | — | — | US | disclosed |
| CN-115124485-A | Benzoxazole derivatives containing sulfoxide as well as preparation method and application thereof | 中国医学科学院药物研究所 | 2022-09-30 | — | — | CN | disclosed |
| CN-106574125-B | Color material dispersion liquid, colored resin composition for color filter, and display device | DNP精细化工股份有限公司 | 2019-05-17 | — | — | CN | disclosed |
| CN-106574999-B | Colored resin composition for color filter, and display device | DNP精细化工股份有限公司 | 2019-03-22 | — | — | CN | disclosed |
| CN-106574999-A | Colored resin composition for color filter, and display device | DNP精细化工股份有限公司 | 2017-04-19 | — | — | CN | disclosed |
| CN-106574125-A | Color material dispersion liquid, colored resin composition for color filter, and display device | DNP精细化工股份有限公司 | 2017-04-19 | — | — | CN | disclosed |
| US-20080132490-A1 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME LLC | 2008-06-05 | — | — | US | disclosed |
| US-20080132490-A1 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME LLC | 2008-06-05 | — | — | US | disclosed |
| US-7220740-B2 | 1,4-diazabicyclo[3.2.2]nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-05-22 | — | — | US | disclosed |
| EP-1289988-B1 | 1,4-DIAZABICYCLO 3.2.2]NONABENZOXAZOLE, -BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SYNTHELABO (FR) | 2004-05-19 | — | — | EP | disclosed |
| US-20030153574-A1 | 1,4-diazabicyclo[3.2.2]nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2003-08-14 | — | — | US | disclosed |
| EP-1289988-A1 | 1,4-DIAZABICYCLO 3.2.2]NONABENZOXAZOLE, -BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001092261-A1 | 1,4-DIAZABICYCLO[3.2.2]NONABENZOXAZOLE, -BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2001-12-06 | — | — | WO | disclosed |
| WO-1994006782-A1 | BENZOXAZOLE AND BEZOTHIAZOLE DERIVATIVES | ZENECA LIMITED (GB) | 1994-03-31 | — | — | WO | disclosed |
| US-4740596-A | Process for preparation of 4-sulfonylthio azetidinone derivatives | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1988-04-26 | — | — | US | disclosed |
| US-4713452-A | Process for preparation of azetidinone derivatives | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1987-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132490-A1 | Substituted diazepan orexin receptor antagonists | HCRTR2, HCRTR1, CRHR1 | ELANE 2925/4885FBP1 1378/4885F2RL3 721/4885 |
| US-20030153574-A1 | 1,4-diazabicyclo[3.2.2]nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof | IL4I1, MT-CO1, CBR1 | ELANE 2863/4885FBP1 1398/4885F2RL3 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.